Exploring extreme conditions for star formation: a deep search for molecular gas in the Leo ring

We carry out sensitive searches for the CO J=1-0 and J=2-1 lines in the giant extragalactic HI ring in Leo to investigate the star formation process within environments where gas metallicities are close to solar but physical conditions are different than those typical of bright galaxy disks. Our aim is to check the range of validity of known scaling relations. We use the IRAM-30m telescope to observe eleven regions close to HI gas peaks or where sparse young massive stars have been found. For all pointed observations we reached a spectral noise between 1 and 5~mK for at least one observed frequencies at 2~km/s spectral resolution. We marginally detect two CO J=1-0 lines in the star forming region Clump~1 of the Leo ring, whose radial velocities are consistent with those of Halpha lines but line widths are much smaller than observed for virialized molecular clouds of similar mass in galaxies. The low signal-to-noise ratio, the small line widths and the extremely low number densities suggest that a more standard population of molecular clouds, still undetected, might be in place. Using upper limits to the CO lines, the most sensitive pointed observations show that the molecular gas mass surface density is lower than expected from the extrapolation of the molecular Kennicutt-Schmidt relation established in the disk of galaxies. The sparse stellar population in the ring, possibly forming ultra diffuse dwarf galaxies, might then be the result of a short molecular gas depletion time in this extreme environment.}Comment: 11 pages, 7 figures, accepted for publication in A&

In Vitro Reduced Susceptibility to Pentavalent Antimonials of a Leishmania infantum Isolate from a Human Cutaneous Leishmaniasis Case in Central Italy

Cutaneous leishmaniasis (CL) caused by Leishmania (Leishmania) infantum is endemic in the Mediterranean basin. Here we report an autochthonous case of CL in a patient living in central Italy with an unsatisfactory response to treatment with intralesional Meglumine Antimoniate and in vitro demonstration of reduced susceptibility to SbIII. Parasitological diagnosis was first achieved by histopathology on tissue biopsy and the patient was treated with a local infiltration of Meglumine Antimoniate. Since the clinical response at 12 weeks from the treatment’s onset was deemed unsatisfactory, two further skin biopsies were taken for histopathological examination, DNA extraction and parasite isolation. L. (L.) infantum was identified by molecular typing. The low susceptibility to Meglumine Antimoniate was confirmed in vitro: the promastigotes from the patient strain showed significantly lower susceptibility to SbIII (the active trivalent form of antimonial) compared to the reference strain MHOM/TN/80/IPT1. The patient underwent a new treatment course with intravenous liposomal Amphotericin B, reaching complete healing of the lesion. Additional studies are needed to confirm the epidemiological and clinical relevance of reduced susceptibility to SbIII of human L. (L.) infantum isolate in Italy

Neoadjuvant Treatment in Rectal Cancer: Actual Status

Neoadjuvant (preoperative) concomitant chemoradiotherapy (CRT) has become a standard treatment of locally advanced rectal adenocarcinomas. The clinical stages II (cT3-4, N0, M0) and III (cT1-4, N+, M0) according to International Union Against Cancer (IUCC) are concerned. It can reduce tumor volume and subsequently lead to an increase in complete resections (R0 resections), shows less toxicity, and improves local control rate. The aim of this review is to summarize actual approaches, main problems, and discrepancies in the treatment of locally advanced rectal adenocarcinomas

No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC)

Epidermal growth factor receptor (EGFR) is usually expressed in squamous cell anal carcinoma (SCAC) and anti-EGFR agents could represent a valid treatment strategy, also considering that KRAS and BRAF mutations are rare events in this type of cancer. However, no data are available on NRAS status in SCAC. In this study we analyzed NRAS status (exons 2-4) by Pyrosequencing in a case series of 50 SCAC patients previously characterized in our laboratory for KRAS, BRAF, PIK3CA mutations and HPV and HIV infections. We found no mutation in NRAS gene. These results confirm that since the principal anti-EGFR resistance mechanisms are almost absent in SCAC, anti-EGFR agents should be considered for the treatment of this type of cancer

Prognostic role of a new inflammatory index with neutrophil-to-lymphocyte ratio and lactate dehydrogenase (CII: Colon Inflammatory Index) in patients with metastatic colorectal cancer: results from the randomized Italian Trial in Advanced Colorectal Cancer (ITACa) study

Aim: The aim of this study was to investigate the role of a new inflammatory index (Colon Inflammatory Index [CII]) as a predictor of prognosis and treatment efficacy in patients with metastatic colorectal cancer (mCRC) enrolled in the prospective multicenter randomized ITACa (Italian Trial in Advanced Colorectal Cancer) trial to receive first-line chemotherapy (CT)+ bevacizumab or CT alone. Patients and methods: Between November 14, 2007 and March 6, 2012, 276 patients diagnosed with CRC were available for baseline neutrophil-to-lymphocyte ratio (NLR) and lactate dehydrogenase (LDH). We divided the population into three groups on basis of the CII index. Results: At baseline in all populations, median PFS and OS was predictive of clinical outcome (p<0.0001). Following adjustment for clinical covariates, multivariate analysis confirmed CII index as an independent prognostic factor. The CII index was also predictive when we evaluated the two distinct arms with (p=0.0009) or without bevacizumab (p=0.0001). When we divided right side versus left side for treatment regimen (CT plus bevacizumab versus only bevacizumab), we found a benefit of bevacizumab versus only CT in the right side in patients treated with bevacizumab and not in patients treated with only chemotherapy. Conversely, we found no difference the left side, but we found a difference in the poor group of 4 months in favor to only chemotherapy. Conclusion: Our results indicate that the CII index is a good prognostic marker for mCRC patients in first line treatment with CT with or without bevacizumab

The Best Management of Portal Neoplastic Thrombosis in Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is the fifth commonest cancer worldwide. Vascular invasion of the portal vein is one of the most important prognostic factors for survival in HCC patients and the prognosis is generally poor. The optimal treatment for patients with HCC and portal vein tumour thrombus (PVTT) remains controversial. Although many therapeutic options have been proposed, surgical resection is the only hope of cure for such patients.We present the case of a 74-year-old man diagnosed with a single HCC nodule with portal thrombosis in the right hepatic lobe in the setting of HCV-related liver cirrhosis. After a first approach with a loco-regional treatment not tolerated by the patient, a right hepatectomy proved the best option. One year later the patient is still free from disease

Protective Role of the M-Sec-Tunneling Nanotube System in Podocytes

Podocyte dysfunction and loss are major determinants in the development of proteinuria. FSGS is one of the most common causes of proteinuria, but the mechanisms leading to podocyte injury or conferring protection against FSGS remain poorly understood. The cytosolic protein M-Sec has been involved in the formation of tunneling nanotubes (TNTs), membrane channels that transiently connect cells and allow intercellular organelle transfer. Whether podocytes express M-Sec is unknown and the potential relevance of the M-Sec-TNT system in FSGS has not been explored